Effect of Dupilumab an mucus plugs and inflammatory patterns in sEvere asThmAtiC paTients — a Pilot Study (DETACT)
Living with severe asthma can be exhausting, especially when thick mucus builds up and blocks the airways. Standard inhalers often do not fully clear these stubborn mucus plugs. This research study, called DETACT, looks at whether an existing biologic medicine called dupilumab (Dupixent) can help. Dupilumab is given as an injection under the skin using a pre-filled pen or syringe. It works by targeting specific proteins that cause inflammation in the lungs. Doctors want to see if calming this swelling helps dissolve mucus plugs, improves airflow, and eases everyday asthma symptoms. The trial is open to adults aged 18 and over who have severe asthma. By taking part, volunteers help researchers learn more about how to tackle airway blockages and improve future treatment options for people with difficult-to-control asthma.
At a glance
What is this study about?
Asthma is a long-term condition that makes the airways sensitive, swollen, and narrow. For many people, everyday inhalers keep symptoms under control. However, those with severe asthma often experience ongoing breathlessness, wheezing, and coughing. In severe cases, the lungs can produce thick, sticky mucus that forms 'plugs'. These plugs can completely block small breathing tubes, making it very hard to get air in and out.
This pilot study focuses on a modern treatment called dupilumab (brand name Dupixent). Dupilumab is a type of medicine known as a biologic. Instead of just opening up the airways for a short time like a blue reliever inhaler, biologics work deep inside the immune system to block signals that trigger allergic swelling and mucus production.
Researchers want to see exactly how well dupilumab breaks down these airway plugs and clears inflammation. Because this is a pilot study, it aims to gather detailed early evidence on whether clearing mucus leads to better lung scans and easier breathing. If successful, this research could help doctors choose the most effective treatments for patients whose asthma does not respond well to ordinary medicines.
Key takeaways
- Tests whether dupilumab injections help clear stubborn airway mucus plugs in severe asthma.
- Open to adults aged 18 and older with difficult-to-control asthma.
- Dupilumab works by dampening down allergic swelling in the lungs.
- Involves regular clinic check-ups, breathing assessments, and pre-filled injections.
- Participation is entirely voluntary, and you can stop at any time.
Who may be eligible?
This trial is for adults aged 18 and older who have been diagnosed with severe asthma. It is designed for people whose asthma remains difficult to manage even when using their regular daily preventer inhalers.
To take part, participants will usually need evidence of severe airway inflammation or mucus buildup. The trial team will review your medical history to make sure dupilumab is safe and appropriate for you.
You may not be eligible if you have other serious lung conditions, active parasitic infections, or if you are currently taking part in another clinical trial testing a new drug. If you are pregnant or planning to become pregnant, the study team will talk through special safety guidelines with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with severe asthma.
- My asthma symptoms persist despite taking regular preventer medication.
- I am able and willing to attend scheduled hospital clinic visits.
- I am comfortable receiving injections under the skin.
What does participation involve?
If you decide to join, you will be invited to a hospital clinic for a screening visit. The medical team will check your overall health, carry out breathing tests (such as spirometry), and may take blood tests or specialized chest scans to look closely at your airways.
During the trial, you will receive dupilumab as a shallow injection just under the skin using a pre-filled syringe, usually once every two weeks. The clinic staff can show you how to do this safely at home, or it can be given during your visits. You will continue to attend regular follow-up appointments so doctors can monitor your lung function, check for side effects, and see if your mucus plugs are clearing. Your participation will last for several months, and you can contact the trial nurses at any point if your symptoms change.
Potential risks and benefits
Locations (1)
- —UnverifiedAustria
Common questions
What is dupilumab?
Dupilumab is an approved injection that calms the immune pathways causing inflammation and mucus in conditions like severe asthma and eczema.
Do I have to stop taking my regular asthma inhalers?
No. You will almost certainly be asked to keep using your usual preventer and reliever inhalers as prescribed alongside the study treatment.
Does the injection hurt?
The injection goes just under the skin of your tummy or thigh. Most people feel only a brief pinch or mild stinging that settles quickly.
Will taking part cost me anything?
No. The study medicine and all tests are provided free of charge, and trial teams often help cover reasonable travel expenses for hospital visits.
What happens if my asthma gets worse during the study?
You will have a clear asthma action plan and direct contact details for the study team, who can adjust your treatment quickly if needed.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.